Frelii Speaks with Potential Partners at CES about the Future of AI in DNA Sequencing and Analysis

SPECIAL TO CES—Executives from Frelii Inc. (OTCQB: FRLI) met with potential partners and prospects from industries including medical cannabis, precision medicine, consumer wellness, insurance and hospital systems during the CES conference in Las Vegas, Nevada. The Frelii team discussed recent advancements in artificial intelligence (AI) systems that are fueling an AI-driven revolution in the field of genomics and DNA sequencing.

“The rapid evolution of AI-based DNA sequencing is delivering new insight into the genome coupled with connections and patterns of gene expression at a scale we have never seen before,” said Ian Jenkins, CEO of Frelii. “Our own Frelii AI system stands at the forefront to empower personalized and precision medicine in new and exciting ways. Frelii looks at every data point on the genome and analyzes how each point is interconnected with every other data point. This is a fundamentally different approach to DNA sequencing and analysis. We produce 60 Million data points, vs the typical 400-700 thousand, as with typical consumer level DNA kits. What we end up with are hard facts that say what the human body will do as well as information regarding what it could do when drugs, medications, supplements and lifestyle changes are introduced.”

Companies are turning to Frelii expertise because with its AI, DNA sequencing and analysis can be completed in a matter of hours, as opposed to weeks or months and at a level that expands the frontiers of knowledge by analyzing massive amounts of data. Most consumer DNA kits on the market look at 400,000 to 700,000 data points along the genome, generating approximately 384 outcomes, such as ancestry, diet suggestions or identification of potential health risks. Frelii’s recently improved technology has dramatically increased the data points subject to analysis to more than 60 million data points, which can generate more than 60 million outcomes. To process each data point against the other data points takes billions of gigabytes of data processing for one person’s physiology. Frelii’s high-efficiency Genetic Sequencing and analysis using Frelii's proprietary technology has increased to greater than 99 percent and 99.999 percent accuracy on whole genome and exome sequencing, respectively.